Table 1.

Cell response induced by HA interactions with its receptors in different cancer models. Data from the past five years

Receptor	Cell response	Model	Reference
CD44	Proliferation	Cholangiocarcinoma cell lines; Non‐small cell lung cancer; Breast carcinoma cells; Colon cancer cells; Breast cancer stem cell‐like cells; Ovarian cancer cells; Pancreatic cancer.	[18, 19, 20, 21, 22, 23, 24]
	Anti‐apoptosis/Survival	Non‐small cell lung cancer; Breast cancer cells; Colon cancer cells; Cancer stem cells of head and neck squamous cell carcinoma.	[19, 20, 21, 25, 26]
	Motility and Invasion	Cholangiocarcinoma cell lines; Breast carcinoma cells; Head and neck squamous cell carcinomas and its cancer stem cells; Ovarian cancer cells.	[18, 23, 26, 27, 28]
	Epithelial to mesenchymal transition	Head and neck squamous cell carcinomas; Breast cancer cells; Liver cancer cells.	[28, 29, 30]
	Stemness	Head and neck squamous cell carcinomas; Breast cancer stem cell‐like cells; Liver cancer cells.	[22, 28, 30]
	Radio/Chemotherapy resistance	Head and neck squamous cell carcinomas; Colorectal cancer; Breast cancer stem cell‐like cells.	[21, 22, 26, 28]
	Metastasis	Head and neck squamous cell carcinomas; Pancreatic cancer.	[24, 28]
RHAMM	Proliferation	Lung adenocarcinoma cells; Ovarian cancer cells; Prostate cancer cells; Breast carcinoma cells; Adenocarcinoma of the breast duct; Non‐small cell lung cancer; Fibrosarcoma cells.	[19, 31, 32, 33]
	Survival	Ovarian cancer cells; Prostate cancer cells; Breast carcinoma cells; Adenocarcinoma of the breast duct; Non‐small cell lung cancer.	[19, 32]
	Motility	Lung adenocarcinoma cells; choriocarcinoma cells.	[31, 34]
	Epithelial to mesenchymal transition; Chemotherapy resistance and stemness	Gastric cancer cells.	[35]
TLR2,4	Inflammation	Melanocytes.	[36]
	Proliferation	Colorectal cancer; Colorectal cancer cells; Glioblastoma stem‐like cells.	[21, 37]
	Anti‐apoptosis/Survival	Colorectal cancer; Colorectal cancer cells.	[21]
	Radiotherapy resistance	Colorectal cancer.	[21]
LYVE‐1	(Lymph node) Metastasis	Breast cancer cells; Oral squamous cell carcinoma; Melanoma cells.	[38, 39, 40]
	Proliferation	Lymphatic endothelial cells.	[41]
	Motility	Breast cancer cells; Lymphatic endothelial cells.	[38]
	Adhesion/Docking and migration (to TME)	Dendritic cells.	[42]
	Lymphangiogenesis	Lymphatic endothelial cells.	[38, 41]
	Tight junctions disruption	Lymphatic vessels endothelium.	[40]
Soluble LYVE‐1	Inhibits cell proliferation	Melanoma cells.	[43]
	Inhibits lymphangiogenesis	Corneal lymphangiogenic models in mice.	[44]
HARE	Proliferation, motility, and inflammation	Lymphatic endothelial cells.	[45]
Layilin	Immunomodulator	Immuno infiltrates in gastric and colon cancers; Infiltrating T cells in liver cancer;	[46, 47]
	Invasion	Glioma cells;	[48]